Merck Healthcare Kgaa, Darmstadt, Germany, An Affiliate Of Merck Kgaa, Darmstadt, Germany

This is an early safety study testing a new cancer drug called M9140 in Chinese patients with advanced colorectal cancer that has stopped responding to standard treatments. The trial will enroll 12 participants to check if the drug is safe and to see early signs of whether it mig…

This study aims to identify which patients with relapsing multiple sclerosis (RMS) respond best to treatment with cladribine tablets. Researchers will follow 367 adults already taking this medication in real-world settings to see how long they stay on treatment and track their sy…

This study is a long-term follow-up for people with lupus who finished a previous 24-week trial of an experimental oral drug called enpatoran. It aims to see how safe and effective the drug is over a much longer period. The study includes about 379 participants with different for…

This study looks back at medical records of 360 Japanese patients with advanced bladder cancer who received avelumab maintenance therapy after initial chemotherapy. Researchers want to understand patient characteristics, treatment patterns, and survival outcomes. The study doesn'…

This early-stage study aims to understand how a new cancer drug called tuvusertib is absorbed, processed, and eliminated by the body. It will involve 12 participants with advanced solid tumors who have run out of standard treatment options. Researchers will track a tiny radioacti…